Saxenda (Liraglutide): How the Daily GLP-1 Works

What is Saxenda?

Saxenda is the brand name Novo Nordisk uses for liraglutide 3.0 mg, a GLP-1 receptor agonist delivered by a once-daily subcutaneous injection into the abdomen, thigh, or upper arm, at any time of day, with or without food. It's FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. The FDA also approved it for adolescents ages 12 to 17 with obesity (specifically, body weight above 60 kg and a BMI corresponding to an adult BMI of 30 or higher) in December 2020. Full prescribing details are in the official Saxenda label.

How it works

Liraglutide works the same way as other GLP-1 receptor agonists: it mimics the body's natural GLP-1 hormone, which increases insulin release when blood sugar is elevated, slows gastric emptying, and signals fullness to the brain. The mechanism is essentially the same biology described in our GLP-1 basics guide; what's different about Saxenda is the dosing pattern (daily, not weekly) and the resulting average results, discussed below.

Starting dose and titration

Like other GLP-1 drugs, Saxenda is started at a low dose and increased gradually to reduce nausea and other GI side effects. The label schedule starts at 0.6 mg once daily for the first week, then steps up by 0.6 mg increments each week, 1.2 mg, then 1.8 mg, then 2.4 mg, reaching the full 3.0 mg maintenance dose by week five. If a step isn't well tolerated, prescribers can extend a dose level by an extra week before increasing further. This mirrors the titration logic covered in our general dosing and titration guide, just on a daily rather than weekly clock.

Average results in the SCALE trial

Saxenda's approval rested on the SCALE Obesity and Prediabetes trial, a 56-week study of over 3,700 adults published in the New England Journal of Medicine. Participants taking liraglutide 3.0 mg lost an average of about 8.0% of body weight, compared with about 2.6% in the placebo group. About 63% of the liraglutide group lost at least 5% of body weight, versus 27% on placebo, and about a third lost more than 10%, versus roughly 11% on placebo. In the adolescent SCALE Teens trial, a meaningfully larger share of liraglutide-treated teens achieved a 5% or greater reduction in BMI compared with placebo. As with any trial average, individual results vary widely, and these numbers describe a study population, not a personal prediction.

Saxenda vs the newer weekly GLP-1s

The pattern is consistent across the trial literature: the newer weekly drugs produced meaningfully larger average weight loss than Saxenda in their respective pivotal trials. That doesn't make Saxenda ineffective, it's an FDA-approved medication with real trial-proven results, just a smaller average effect than the drugs that followed it. See our honest comparison of GLP-1 options for weight loss for the fuller picture across the drug class.

Saxenda vs Victoza: same drug, different job

Liraglutide is sold under two brand names for two different purposes. Victoza is dosed up to 1.8 mg daily and is FDA-approved to treat type 2 diabetes. Saxenda is dosed higher, at 3.0 mg daily, and is FDA-approved for chronic weight management. They are not interchangeable; the dose and approved use differ, and a clinician prescribes the product that matches the indication being treated.

Side effects and safety

Saxenda's side-effect profile mirrors the rest of the GLP-1 class: nausea is the most common reaction (reported in roughly 39% of liraglutide users in trials versus about 14% on placebo), along with diarrhea, constipation, vomiting, injection-site reactions, and headache. Like other GLP-1 and dual-agonist drugs, Saxenda carries a boxed warning about thyroid C-cell tumors seen in rodent studies (human relevance hasn't been established), and it's contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Our contraindications and warnings guide covers this in more detail across the whole drug class.

Who might consider Saxenda

Because the weekly drugs tend to produce larger average results, Saxenda is no longer most people's first choice for weight management, but there are real reasons a clinician might recommend it: someone may not tolerate the weekly options well, may prefer daily dosing for other reasons, or their specific insurance plan's coverage rules may point toward it. That said, we couldn't find a strong, citable general clinical or policy source establishing daily dosing itself as a broad medical advantage, so treat any specific insurance step-therapy requirement as plan-specific rather than universal, and confirm your own plan's rules directly. Our cost and insurance guide covers how coverage decisions typically work.

Frequently asked questions